Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care

被引：211

作者：

Launay-Vacher, Vincent ^{[1
]}

Rey, Jean-Baptiste ^{[2
]}

Isnard-Bagnis, Corinne ^{[1
]}

Deray, Gilbert ^{[1
]}

Daouphars, Mikael ^{[3
]}

机构：

[1] Hop La Pitie Salpetriere, Dept Nephrol, ICAR, F-75013 Paris, France

[2] Hop Robert Debre, Dept Pharm, Reims, France

[3] Henri Becquerel Canc Ctr, Dept Pharm, Rouen, France

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2008年 / 61卷 / 06期

关键词：

platinum salts; cisplatin; renal toxicity;

D O I：

10.1007/s00280-008-0711-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).

引用

页码：903 / 909

页数：7